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Objectives. This study sought to establish the prognostic value 
of intravenous dipyridamole technetium.99m (Tc.99m) sestamibi 
single-photon emission computed tomographic (SPECT) myocar- 
dial perfusion imaging. 
Background. Optimal management of patients with coronary 
artery disease involves strategies designed to reduce the risk of 
myocardial infarction and cardiac death. The role of myocardial 
perfusion imaging using newer clinical techniques to determine 
risk and possible benefit from therapy has not been evaluated. 
Methods. Myocardial imaging results were classified as normal 
or abnormal (fixed or reversible defects; small, moderate or 
large). Follow-up evaluation of all patients included the occur- 
rence of cardiac death or nonfatal myocardial infarction and other 
cardiac-related hospital admissions. 
Results. During a mean (+SD) follow-up period of 12.8 -+ 6.8 
months in 512 patients, 25 had a cardiac event. Patients with 
abnormal perfusion had significantly more cardiac events than 
those with normal perfusion (22 vs. 3, p < 0.01). Patients with 
reversible defects had the highest event rates (8.6%), and those 
with normal study results had a very low event rate (1.4%). Large 
defects were strongly associated with more cardiac events and 
hospital admissions than either normal scan results or abnormal 
results showing small defects. 
Conclusions. Patients with normal study results or a small 
defect after intravenous dipyridamole Tc-99m sestamibi SPECT 
imaging had an excellent short-term prognosis. Those with abnor- 
mal results (reversible or large defect) had an increased risk of 
subsequent cardiac death, nonfatal myocardial infarction and 
other cardiac-related hospital admissions. 
(J Am Coil Cardiol 1995;26:1202-8) 
Optimal management of patients with coronary artery disease 
involves trategies designed to reduce the risk of the devastat- 
ing effects of the disease, primarily myocardial infarction and 
cardiac death. Ideally, the evaluation of patients with known or 
suspected coronary artery disease should discriminate between 
those patients who are at high risk and may benefit from 
aggressive therapies and those at low risk who may be managed 
best conservatively. High risk patients include those with 
multivessel coronary artery disease, particularly if there is 
evidence of either ischemia or left ventricular dysfunction 
(1-4). Previous tudies with exercise planar thallium-201 myo- 
cardial perfusion imaging have shown that patients with isch- 
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emic defects are at increased risk for cardiac events (5-8). In 
contrast, patients with normal imaging results have an excel- 
lent prognosis, even in the presence of coronary artery disease 
(5,6). Several studies (9,10) have demonstrated that risk strat- 
ification that includes myocardial perfusion imaging provides 
superior prognostic information compared with cardiac athe- 
terization alone. 
Recently, substantial changes have occurred in the field of 
nuclear cardiology that have resulted in improved techniques 
and a broader referral base. Single-photon emission computed 
tomographic (SPECT) imaging has largely replaced planar 
imaging, and technetium-based imaging agents have become 
available as alternatives to thallium-201 (11,12). Additionally, 
as the target population ages, fewer patients are able to 
exercise adequately, and pharmacologic stress testing, such as 
with dipyridamole, is being used more frequently (13-15). 
Currently, few data are available in patients undergoing dipyr- 
idamole SPECT imaging with technetium-99m (Tc-99m) im- 
aging agents (16,17). Therefore, the present study sought o 
determine the independent predictive value for future cardiac 
events of Tc-99m sestamibi SPECT imaging using intravenous 
dipyridamole in a group of consecutive patients evaluated for 
known or suspected coronary artery disease. Because of the 
potential impact on the health care system, the value of this 
technology in predicting cardiac-related hospital admissions, 
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including those for congestive heart failure and unstable 
angina, was evaluated. 
Methods 
Study design and patient selection. This was a prospective 
study of 604 consecutive patients who underwent intravenous 
dipyridamole Tc-99m sestamibi SPECT imaging at either 
Memorial Hospital of Rhode Island or Roger Williams Med- 
ical Center (>18 months). Patients were referred by an 
attending physician for dipyridamole stress with nuclear imag- 
ing because of an inability or limited capacity to exercise. At 
the initial interview, acardiac history and risk factor question- 
naire was completed by each patient and discussed with the 
physician performing the test. 
Dipyridamole/Tc99m-sestamibi scintigraphy. Patients re- 
ported for testing in a fasting state and refrained from products 
containing methylxanthines for the 24 h preceding testing. 
Dipyridamole was intravenously administered at a rate of 
0.56 mg/kg body weight (range 21.6 to 75.3) over 4 min (15). 
Patients underwent either 2-day (558 patients) or 1-day (55 
patients) rest-stress tudies. Technetium-99m sestamibi (mean 
[_+SD] 18.8 _+ 3.5 mCi, range 14.2 to 30.6) was injected 7 to 
9 min after the start of the dipyridamole infusion. The mean 
dose of Tc-99m sestamibi administered at rest was 17.3 _+ 3.9 
mCi (range 7.1 to 30). 
Tomographic imaging was performed using an ADAC ARC 
4000 rotating-head gamma camera equipped with 61 photo- 
multiplier tubes, a 6.5-ram sodium iodide crystal and a low 
energy, high resolution, parallel-hole collimator. Sixty-four 
projections (20 s for stress, 25 s for rest) were obtained over a 
180 ° semicircular arc extending from the 45 ° right anterior 
oblique to the 45 ° left posterior oblique position. For 2-day 
studies, filtered back-protection was performed using a Butter- 
worth filter with a frequency cutoff of 0.5 cycles/pixel on the 
order of 10 for reconstruction of the transaxial slices to a 
thickness of 6.6 mm. For the 1-day stress image, a frequency of 
0.6 cycles/pixel on the order of 7 was used. No preprocessing 
filtration or attenuation correction was used. 
Image interpretation. All studies were interpreted by con- 
sensus of two experienced nuclear cardiologists. The short- 
axis, vertical ong-axis and horizontal long-axis lices, qualita- 
tive bullseye images and unprocessed planar data were 
available for interpretation. Imaging results were classified as 
either normal or abnormal, and the latter required an esti- 
mated 30% to 40% improvement between stress and rest 
images to be classified as reversible. Abnormal imaging results 
were also classified according to extent of photon deficiency: 
small (well contained within one vascular territory), moderate 
(two vascular territories) and large (three vascular territories). 
Follow-up evaluation. Outcome information was solicited 
for all patients enrolled in the study. Patients or immediate 
family members were initially contacted by telephone. If not 
contacted, letters were sent to patients requesting a response, 
or referring physicians were consulted. Each reported hospital 
admission, death, cardiac catheterization r revascularization 
procedure was confirmed by review of hospital records or 
death certificates, or both, by a member of the study team who 
had no knowledge of the patient's imaging results. Cardiac 
events were restricted to documented cardiac death or nonfa- 
tal myocardial infarction. For each patient, only the first 
recorded cardiac event was used in the statistical analysis. The 
occurrence and timing of coronary artery bypass surgery or 
percutaneous transluminal coronary angioplasty and hospital 
admission for unstable angina pectoris or congestive heart 
failure and death from any cause were also documented. 
Forty-nine patients (all with abnormal scan results) who un- 
derwent coronary revascularization within the first 6 months 
after the dipyridamole study were excluded from the analysis 
because the interventions may have been based on image 
results, and the intervention itself may have affected the 
occurrence of cardiac events. Patients who underwent coro- 
nary revascularization after 6 months were recorded as such, 
and their data were censored thereafter. 
Statistical methods. Preselection of prognostic variables 
was limited to patients in the analysis group. To select possible 
predictors or modifiers of outcome, demographic and clinical 
information on evaluable patients was tabulated by patients 
with or without an event. Comparisons between the two groups 
were made using the Student t test with respect o continuous 
variables and the Fisher exact test with respect o discrete 
variables. Additionally, the odds ratio and 95% confidence 
limits from the logistic regression procedure were estimated by 
univariate analysis for each of these variables. Statistical 
significance was declared at p -< 0.05. Variables that showed a 
statistically significant difference between the two groups were 
used as possible predictors in the Cox proportional hazards 
regression model for prognostication f an event (18,19). In 
addition to demographic and clinical characteristics, imaging 
results were stratified by patients with and without events. 
Comparisons of abnormal to normal, reversible to normal, 
fixed to normal and reversible to fixed were made. The 
Bonferroni's correction was used to adjust for multiple com- 
parisons of reversible to normal, fixed to normal and reversible 
to fixed (20). 
Two models were constructed to evaluate the relation of 
1) abnormal imaging results relative to normal results, and 
2) reversible defects relative to normal results and fixed defects 
relative to normal results. The comparison between patients 
with and without events was reported in terms of the relative 
risk for Cox proportional hazards regression and correspond- 
ing 95% confidence interval. In addition to using a full model 
of selected predictive variables (significant demographic and 
clinical characteristics from the univariate analyses) and imag- 
ing results for the prognostication f an event, a stepwise 
selection procedure was also used in the Cox proportional 
hazards regression procedure to give a reduced model of 
significant independent predictors. Variables were entered 
into the model at a significance l vel of p -< 0.15 and were 
removed if the significance l vel was p > 0.05. 
The relation between perfusion imaging results and time to 
an event was examined graphically by Kaplan-Meier curves. 
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Table 1. Comparison of Imaging Results With Cardiac Events, Death (All Causes) and 
Hospital Events 
Imaging Results Abnormal Imaging Results 
Total Normal Abnormal Reversible Fixed 
(n = 512) (n = 216) (n = 296) (n = 221) (n = 75) 
Cardiac events 25 (4.9%) 3 (1.4%) 22 (7.4%)* 19 (8.6%)* 3 (4.0%) 
Cardiac death 12 (2.3%) 1 (0.5%) 11 (3.7%)t 8 (3.6%) 3 (4.0%) 
Nonfatal MI 13 (2.5'~) 2 (0.9%) 11 (3.7%) 11 (5.0%) 0 (0.0%) 
Death (all causes) 33 (6.4%) 7 (3.2%) 26 (8.8%)t 19 (8.6%) 7 (9.3%) 
Hospital 50 (9.8%) 11 15.l%) 39 (13.2%)* 30 113.6%)* 9 (12.0%) 
admissions:~ 
CHF 23 (4.5%) 2 (0.9q'b) 21 (7.1%)* 15 (6.8%)* 6 (8.0%)* 
Unstable angina 33 (6.4%) 9 (4.2%) 24 (8.1%) 18 (8.1%) 6 (8.0%) 
Reva~ularization 8 (1.6%) 2 (0.9%) 6 (2.0%) 4 (1.8%) 2 (2.7%) 
*p < 0.01, +p < 11.05 versus patients with normal imaging results. ~:Patient could have one or more hospital 
admissions. Bonferroni correction was used to adjust for multiple comparisons. Data presented are number (%) of 
patients. CHF = congestive h art failure; MI - myocardial nfarction. 
Two analyses were performed: 1) comparison of abnormal and 
normal imaging results, and 2) comparison of reversible and 
fixed defects, respectively, versus normal images. The log-rank 
statistic was used to make comparisons between the curves. 
Resu l ts  
Patient characteristics. Of 604 patients who underwent 
rest and stress Tc-99m sestamibi SPECT imaging, follow-up 
information was available for 561 (93%). In addition, 49 
patients were referred for early revascularization within 6 
months of the dipyridamole t st and were excluded. Therefore, 
512 patients constituted the evaluable analysis group. The 
evaluable and nonevaluable patients were comparable with 
respect o all demographic and clinical characteristics with the 
exception that previous myocardial infarction was higher in the 
nonevaluable patients (p < 0.05). The majority of patients 
were women (56.4%), and the average age of patients was 67.2 
years (range 32 to 91). 
Association of myocardial perfusion imaging results with 
cardiac events. Of the 512 patients, 216 (42.2%) had normal 
imaging results, and 296 (57.8%) had abnormal results (221 
reversible, 75 fixed). Mean follow-up period 12.8 _+ 6.8 months 
(range 1.6 to 31.4). There were 25 cardiac events (12 cardiac 
deaths, 13 nonfatal myocardial infarctions) and 83 other events 
(death from all causes or other cardiac-related hospital admis- 
sions). The relations between all events and imaging results are 
presented in Table 1. A cardiac event rate of 1.4% (3 of 216) 
for patients with normal imaging results was significantly (p < 
0.01) less than that of 7.4% (22 of 296) for patients with 
abnormal imaging results. The stratification of abnormal im- 
aging results into reversible or fixed defects showed that 
patients with reversible defects had significantly more events 
(8.6%) than those with normal results, but the increase in 
event rate for those with fixed defects (4.0%) did not reach 
statistical significance. 
Relative risk of selected clinical and scintigraphic vari- 
ables. A summary of the univariate comparison of demo- 
graphic and baseline characteristics between patients with and 
without cardiac events is presented in Table 2. Age did not 
differ between the two groups, but patients who had a cardiac 
event were significantly more likely to be male and to have 
diabetes mellitus. The best univariate predictor of events 
remained abnormal imaging results, especially with reversible 
defects (odds ratio [OR] 5.70 and 6.68, respectively). 
Cox proportional hazards regression analysis. The results 
of the Cox proportional hazards regression analysis are pre- 
sented in Table 3. In model I, patients with abnormal imaging 
results had approximately a fourfold increase (p < 0.05) in the 
relative risk of a cardiac event compared with those with 
Table 2. Imaging and Baseline Characteristics Stratified by Patients 
With and Without a Cardiac Event 
Cardiac 
Event No Event Odds Ratio 
(n = 25) (n = 487) (95% CL) 
Age (yr)* 68,8 = 10.1 67.2 _+ ll.2 1.01 (0.98, 1.05) 
Male gender 17 (68%) 206 (42%) 2.90 (1.23, 6.85)t 
Medical history 
Diabetes mellitus 13 (52%) 117 (24%) 3.43 (1.52, 7.71):~ 
Hypertension 17 (68%) 282 (58%) 1.55 (0.65, 3.65) 
Current smoker 14 (56%) 213 (44%) 1.64 (0.73, 3.68) 
Previous MI 1 l (44%) 126 (26%) 2.25 (I.00, 5.09) 
Imaging results 
Normal 3 (12%) 213 (44%) 1.00[] 
Abnormal 22 (88%) 274 (56%) 5.70 (1.68, 19.30)][¶ 
Reversible defects 19 (76%) 202 (42%) 6.68 (1.95, 22.91)1['[[ 
Fixed defects 3 (12%) 72 115%) 2.96 (0.58, 14.99)[ [ 
*Mean _+SO. t'p < 0.05, :~p < 0.01 versus patients with cardiac event, riP < 
1t.05 versus normal image. ~lp < 0.01 versus patients with normal imaging results. 
Bonferroni correction was used to adjust for multiple comparisons. Unless 
otherwise indicated, ata re number (%) of patients. CL = confidence limits; 
M1 - myocardial nfarction. 
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Table 3. Cox Proportional Hazards Regression Analysis for 
Predicting Risk of Cardiac Events 
Predictor 
Model I Model 1I 
Odds Ratio Odds Ratio 
(95% CL) (95% CL) 
Age (yr) 1.01 (0.97, 1.05) 1.01 (0.97, 1.05) 
Male gender 2.28 (0.97, 5.36) 2.28 (0.97, 5.36)* 
Diabetes mellitus 3.07 (1.36, 6.90)*+ 2.93 (1.25, 6.42)*~ 
Abnormal imaging results 3.73 (1.08. 12.93)*:~ 
Reversible defects - -  4.41 (1.25, 15.61)*:~ 
Fixed defects - -  2.11 (0.42, 10.63) 
*p < 0.05, predictors identified by stepwise procedure, fp < 0.01, :]:p < 0.05, 
predictors bymultivariate Cox proportional h zards regression. CL = confidence 
limits. 
normal results. A history of diabetes mellitus also was a 
significant independent predictor of cardiac events, although 
not to the same magnitude as abnormal results. When the 
presence of a reversible or fixed defect was included, and that 
of abnormal imaging results excluded (model II), patients with 
reversible defects had a 4.4-fold increase in the relative risk of 
a subsequent cardiac event. 
Eighteen-month cardiac event-free survival analysis. The 
relation of time to cardiac event by perfusion imaging was 
evaluated. The presence of abnormal imaging results was 
associated with a significant (p < 0.01) decrease in event-free 
survival compared with the presence of normal results. The 
18-month event-free survival was 98.3% and 90.3%, respec- 
tively, for patients with normal and abnormal imaging results. 
A similar comparison ofevent-free survival patterns of patients 
with normal results or reversible or fixed perfusion defects 
is presented in Figure 1. Event-free survival was significantly 
(p < 0.01) decreased in patients with reversible defects com- 
pared with those with normal imaging results (98.3% for 
Figure l. Cardiac event-free survival patterns ofpatients with revers- 
ible or fixed perfusion defects and patients with normal imaging 
results. Event-free survival was significantly (p < 0.01) decreased in 
patients with reversible defects compared with those with normal 
results (98.3% for normal results, 87.7% for reversible defects at 18 
months). 
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normal results, 87.7% for reversible defects at 18 months). 
However, event-free survival associated with reversible defects 
did not differ significantly from that with fixed defects, al- 
though a trend toward fewer events in patents with fixed 
defects was demonstrated. 
Relation of cardiac events to defect severity. The relation 
of cardiac events to the extent of the perfusion defect as 
analyzed by Cox proportion hazards regression ispresented in
Table 4. Those patients with small defects had a risk of cardiac 
events imilar to those with normal imaging results, but the risk 
increased ramatically in the groups with moderate and large 
defects (relative risk 3.02 and 6.77, respectively) and were 
statistically significantly different. 
Cardiac-related hospital admissions. Hospital admissions 
due to cardiac causes other than myocardial infarction or 
cardiac death were compared with imaging results. Stepwise 
Cox proportional hazards regression demonstrated that abnor- 
mal scan results, with either eversible or fixed defects, were 
independent predictors of such hospital admissions (OR 3.38, 
95% CL 1.61, 7.09 and 2.75 OR, 95% CL 1.08, 7.00, respec- 
tively). Cardiac-related hospital admissions also were evalu- 
ated in relation to defect extent (Table 4) using both stepwise 
and multivariate Cox proportional hazards regression. The 
greatest predictor of a future hospital admission was a large 
defect (multivessel pattern). The relation between both per- 
centages of cardiac events and cardiac-related hospital admis- 
sions and defect size is presented inFigure 2. For patients with 
a large defect, the annual event rate was >30%. 
Discuss ion  
The present study in 512 patients demonstrates that pa- 
tients with normal intravenous dipyridamole Tc-99m sestamibi 
SPECT imaging results have an excellent prognosis but that 
those with abnormal results, especially with reversible defects, 
have significantly more cardiac events. In addition, the relative 
risk of cardiac events and other cardiac-related hospital admis- 
sions was highest in those patients with moderate or large 
defects. 
Comparison with other myocardial perfusion imaging stud- 
ies. The prognostic value of exercise testing with thallium-201 
myocardial perfusion imaging is well established (8). Although 
most previous studies have involved planar imaging, recent 
reports by Iskandrian et al. (9) and Machecourt et al. (21) have 
extended the prognostic role to exercise SPECT imaging with 
thallium-201. Fewer data are available for pharmacologic 
imaging, particularly with technetium-based imaging agents 
(16,17). Hendel et al. (22) reported on the largest series of 
patients with dipyridamole (n = 561) and found that abnormal 
planar thallium-201 image results were a significant and inde- 
pendent predictor of cardiac events. Results from the present 
study corroborate and extend these findings both to tomo- 
graphic imaging and to the technetium-based imaging agent 
sestamibi. Miller et al. (23) recently reported on the prognostic 
use of dipyridamole with tomographic T -99m sestamibi imag- 
ing, but in patients with unstable coronary syndromes and with 
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Table 4. Cox Proportional Hazards Regression Analysis for 
Predicting Risk of Cardiac Events and Future Cardiac-Related 
Hospital Admissions Compared With Extent of Defect 
Predictor 
No. of Relative 
No. (%) Events Risk 
of Pts (%) (95% CL) 
Cardiac events 
Age 1.01 (0.98, 1.05) 
Male gender 2.04 (0.86, 4.84) 
Diabetes mellitus 3.18 (1.41, 7.17)*+ 
Extent of defect 
Small 64 (22%) 1 (1.5%) 1.13 (0.12, 10.97) 
Moderate 144 (49%) 10 (6.9%) 3.02 (0.79, 11.57)t 
Large 88 (30%) 11 (12.5%) 6.77 (1.83, 25.08)*t 
Future hospital admissions 
Age 1.02 (0.99, 1.05) 
Male gender 0.49 (0.27, 0.90) 
Diabetes mellitus 2.07 (1.01, 4.22)*t 
Extent of defect 
Small 64 (22%) 4 (6%) 1.42 (0.44, 4.61)*t 
Moderate 144(49%) 17(12%) 2.72 (1.21, 6.11)*t 
Large 88 (30%) 18 (20%) 5.89 (2.65, 13.11):~ll 
*p < 0.01, :~p < 0.05, predictors by Cox proportional hazards regression. 
tp < 0.01, PrP < 0.05, predictors identified by stepwise procedure. CL = 
confidence limits; Pts = patients. 
fewer subjects (23-25). Their results were similar, although 
with a much higher event rate because of the unstable nature 
of the patients. Results from the present study are important 
because the large, unselected cohort is most likely more 
representative of the clinical practice in many communities. 
These prognostic findings with dipyridamole are particu- 
larly important in risk stratification strategies because an 
increasingly greater segment of the target population is unable 
to exercise adequately (26). In many laboratories, pharmaco- 
logic stress now accounts for 30% to 40% of all imaging 
studies. The imaging results with dipyridamole stress carry 
Figure 2. Annual percent of cardiac events (cardiac death, nonfatal 
myocardial infarction) and cardiac-related hospital admissions (con- 
gestive heart failure, unstable angina pectoris, revascularization) in 
relation to defect size (small, moderate, large). Results demonstrate a 
progressive increase inthe percent of both cardiac events and hospital 
admissions with increasing size of defects. 
30 30 
25 25 
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added importance because patients less frequently have symp- 
toms of angina or reversible ECG changes with dipyridamole 
than with exercise, and reliance on imaging data is crucial (27). 
Assignment of risk based on defect extent. An important 
finding of the present study is that increasing defect extent 
portends a high risk of cardiac events and cardiac-related 
hospital admissions, reaching as high as 30% annually for 
patients with defects suggestive of multivessel disease. The 
concept of the importance of defect size has been demon- 
strated previously for exercise stress thallium-201 imaging but 
not for pharmacologic imaging (8,9,21,28). To our knowledge, 
this study is the first to describe the prediction of both cardiac 
events and cardiac-related hospital admissions in relation to 
imaging patterns. Establishing the significance of defect size 
has considerable importance in clinical decision making. Pa- 
tients with multivessel ischemia, implied by the large defect 
size, may benefit most from intervention (3,4), but those with 
smaller defects may not require invasive therapeutic strategies. 
In addition, patients with large defects also may benefit from 
more aggressive strategies designed to reduce hospital admis- 
sions, such as angiotensin-converting e zyme inhibitor therapy 
or use of antiischemic drugs. In the present study, defect 
severity also was analyzed and provided information similar to 
defect extent. 
The relation demonstrated between defect size and inci- 
dence of cardiac events is also of importance because of 
reported ifferences in defect size between thallium-201 and 
Tc-99m sestamibi. Several studies (29-31) have suggested that 
exercise-induced defects in the same patients are smaller after 
sestamibi injection than with thallium-201. Such differences 
may be greater with dipyridamole because of the nonlinear 
relation of Tc-99m sestamibi at higher myocardial blood flow 
(32). Recent data by Santos-Ocampo etal. (33) corroborated 
this by reporting similar Tc-99m sestamibi defects between 
exercise and pharmacologic stress. An implication of these 
studies is that sestamibi may underestimate clinically impor- 
tant ischemia. However, our results illustrate the correlation of 
cardiac events with defect size, confirming the value of esti- 
mating disease xtent and prognosis with Tc-99m sestamibi. 
Importance of normal study results. A very important 
aspect of risk stratification with dipyridamole-sestamibi imag- 
ing is the ability to identify patients who may require no further 
evaluation or intervention. Results from the present study 
demonstrate hat those patients with normal imaging results 
have a very low event rate, <2%/year, which is comparable to 
expected event rates in the general population (34). Those 
patients with abnormal scan results but small defects also had 
an excellent prognosis. Similar results for normal scan findings 
have been found in other studies (35,36) with myocardial 
perfusion imaging using both planar and tomographic tech- 
niques. 
Limitations of the present study. The present report was 
designed as a clinical study in which results were given to 
referring physicians, who then made decisions regarding their 
individual patients. As such, the results may have influenced 
the management and subsequent outcome of patients. To 
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reduce the potential impact of the study results on clinical 
outcome, patients who underwent coronary revascularization 
within 6 months of imaging were excluded. 
At study commencement, no quantitation procedure was 
available for Tc-99m sestamibi SPECT imaging. Lack of 
quantitation may have influenced the results obtained. How- 
ever, the consensus image interpretation used in the present 
study successfully stratified patients into high and low risk 
subgroups. Quantitation might be expected to further separate 
the subgroups by minimizing false positive and false negative 
results. 
Clinical implications. In the future, health care reform will 
most likely require strategies to demonstrate which interven- 
tions affect outcome. Indeed, optimal patient care also requires 
a clear understanding of the natural history of coronary artery 
disease and its risks. Risk stratification of patients with known 
or suspected coronary artery disease is crucial in identifying 
patients likely to benefit from intervention. Data from the 
present study demonstrate that use of dipyridamole with 
Tc-99m sestamibi tomographic imaging is useful in such risk 
stratification. Patients who are at low risk for a cardiac event or 
cardiac-related hospital admission can be identified on the 
basis of normal or mildly positive tomographic imaging results. 
By contrast, patients with large reversible defects are at a 
higher risk and are more likely to benefit from further evalu- 
ation and possibly intervention. From a health care manage- 
ment perspective, patients with abnormal imaging results also 
impact on the system with a greater frequency of cardiac- 
related hospital admissions. The clear distinction between 
patients at low and high risk for either cardiac events or 
cardiac-related hospital admissions is an important aspect of 
myocardial perfusion imaging and may separate it from other 
noninvasive or invasive procedures in which the risk stratifica- 
tion is less predictive of these outcomes. 
We gratefully acknowledge the assistance of Rhonda Jenkins, MS, and Tsushung 
A. Hua, PhD, in statistical analysis, and Rosemary Kerwin, RPh, in manuscript 
preparation. 
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